UNSPSC 51272601: Anileridine

This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71Q1A3O279, chemically known as 4-piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester but generally known as anileridine, which bears US NIH Compound Identifier 8944. Anileridine most often comes in base, dihydrochloride, and hydrochloride forms.

UNSPSC 51272601 Anileridine is a Commodity code that nominally refers to a single opioid pharmaceutical product, but recent state and local procurement activity under this code spans a much broader range of pharmaceutical and health-system goods — naloxone, over-the-counter products, and generic multi-source pharmaceuticals sourced through cooperative purchasing arrangements and direct state procurement channels. State and local buyers using this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work being solicited involves securing pharmaceutical products for distribution through authorized wholesalers, community health initiatives, and state employee or Medicaid benefit programs, with vendors required to meet FDA compliance, Good Manufacturing Practice certification, Drug Supply Chain Security Act adherence, and insurance coverage minimums. Pricing models range from fixed-fee to net-price and WAC-minus structures, with administrative fees and performance penalties common contract terms.

Procurement activity appears concentrated in the South and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline. The Texas Health and Human Services Commission issued Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program supporting self-insured employee health plans and state agencies, with no formal timeline or budget identified. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026, evaluation weighted heavily toward price competitiveness at 75 percent, and contract effectiveness July 1, 2026.